Management of “Ultra-High Risk” Gestational Trophoblastic Neoplasia at a Tertiary Center in India

Abstract

Aims: The aim of this study is to identify clinicopathological features associated with increased morbidity and mortality in cases of “ultra-high risk” gestational trophoblastic neoplasia (GTN) and to compare initial low-dose etoposide-cisplatin (EP) induction chemotherapy with respect to etoposide methotrexate adriamycin cyclophosphamide vincristine (EMACO) regimen. Settings and Design: This was a retrospective study of patients of high-risk GTN from January 2012 to December 2016 with criteria mentioned as “ultra-high-risk group;” pathological or suspected diagnosis of choriocarcinoma, multiple (>20) pulmonary metastases or associated with hemoptysis, brain metastases, large-volume liver metastases, profuse vaginal bleeding, human chorionic gonadotropin >1000,000 IU/L, interval since the last antecedent pregnancy of >2.8 years. Subjects and Methods: Comparison between the two groups of chemotherapy regimens and the median number of chemotherapy courses required to achieve complete remission was done Statistical Analysis Used: Data were analyzed using the SPSS software version 18 and Fisher's exact test with P value statistically significant at the level of 0.05. Results: Thirty-seven cases were high-risk GTN and 24 were “ultra-high risk.” The higher percentage of patients underwent remission of disease following low-dose induction chemotherapy as compared to primary EMACO therapy, 71.4% versus 58.8%. No resistance to second-line chemotherapy was noted, and no surgical intervention was required in the patients receiving low-dose induction chemotherapy before EMACO. Conclusions: We noted a decrease in the proportion of patients developing resistance to primary chemotherapy and lesser adverse effects in those receiving initial low-dose induction EP chemotherapy.

Keywords

Choriocarcinoma - EMACO regimen - gestational trophoblastic neoplasia - high risk gestational trophoblastic neoplasia - low-dose etoposide-cisplatin

Publication History

Received: 29 October 2018

Accepted: 10 November 2019

Article published online:
28 June 2021

• References

• 1 Hussain A, Aziz SA, Bhatt GM, Lone AR, Hussain HI, Wani B. et al. Gestational trophoblastic neoplasia: Experience from a tertiary care center of India. J Obstet Gynaecol India 2016; 66: 404-8
• 2 Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010; 376: 717-29
• 3 Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK. et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2015; 131 Suppl 2: s123-6
• 4 Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R. et al. EP by EMA/CO for high-risk gestational trophoblastic neoplasia: Good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013; 31: 280-6
• 5 May T, Goldstein DP, Berkowitz RS. Review article current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemother Res Pract 2011; 2011: 806256
• 6 Lybol C, Thomas CM, Blanken EA, Sweep FC, Verheijen RH, Westermann AM. et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer 2013; 49: 860-7
• 7 Coleman RE, Seckl MJ. Coleman RE, Seckl MJ. Ultra High Risk GTN: What is it and HOW should we manage it? In: International Society for the Study of Trophoblastic Diseases (ISSTD) GTD book. Ch. 18. p. 1-12.
• 8 Stevens FT, Katzorke N, Tempfer C, Kreimer U, Bizjak GI, Fleisch MC. et al. Gestational trophoblastic disorders: An update in 2015. Geburtshilfe Frauenheilkd 2015; 75: 1043-50
• 9 Lybol C, Thomas CM, Blanken EA, Sweep FC, Verheijen RH, Westermann AM. et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer 2013; 49: 860-7
• 10 Brown J, Naumann RW, Seckl MJ, Schink J. 15 years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. Gynecol Oncol 2017; 144: 200-7